Heartflow (NASDAQ:HTFL) Given New $43.00 Price Target at Canaccord Genuity Group

Heartflow (NASDAQ:HTFL) had its price target upped by Canaccord Genuity Group from $40.00 to $43.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on HTFL. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Wells Fargo & Company reduced their price target on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Heartflow currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Heartflow Stock Up 1.6%

NASDAQ:HTFL opened at $25.89 on Thursday. The business’s 50-day simple moving average is $27.01 and its two-hundred day simple moving average is $30.45. Heartflow has a 52 week low of $20.13 and a 52 week high of $41.22. The stock has a market cap of $2.20 billion and a PE ratio of -14.30.

Insider Buying and Selling

In related news, Director Julie A. Cullivan sold 9,122 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total value of $228,050.00. Following the completion of the sale, the director directly owned 27,291 shares in the company, valued at $682,275. This trade represents a 25.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the transaction, the insider directly owned 10,448,158 shares of the company’s stock, valued at $293,070,831.90. The trade was a 16.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 2,117,674 shares of company stock worth $59,052,646.

Hedge Funds Weigh In On Heartflow

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new position in shares of Heartflow during the fourth quarter valued at approximately $27,000. TFC Financial Management Inc. purchased a new stake in Heartflow in the 3rd quarter valued at about $40,000. Russell Investments Group Ltd. bought a new position in Heartflow in the 4th quarter worth about $45,000. Legal & General Group Plc bought a new position in Heartflow in the 3rd quarter worth about $59,000. Finally, Strs Ohio purchased a new position in Heartflow during the 4th quarter worth $99,000.

Key Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong growth — HeartFlow reported Q4 revenue of $49.13M (vs. $46.58M consensus) and year-over-year revenue growth of ~40.5%, a key driver for optimism about adoption and recurring revenue. Earnings Release / Transcript
• Positive Sentiment: Canaccord raised its price target to $43 and maintained a Buy rating — this is a constructive analyst signal that implies sizeable upside from current levels and likely supported the intraday gain. Canaccord Raise (Benzinga)
• Positive Sentiment: Longer-term growth narrative—coverage noting HeartFlow as an AI/advanced-imaging beneficiary may be underpinning investor interest in the stock’s growth prospects. AI Beneficiary Article (MSN)
• Neutral Sentiment: Analyst & research coverage continues — independent write-ups and the full earnings call transcript provide more detail for investors to reassess forecasts and growth assumptions. Seeking Alpha Analysis Earnings Call Transcript
• Negative Sentiment: EPS miss and analyst target trims — Q4 EPS was ($0.29) vs. consensus ($0.16), a notable downside vs. expectations that tempers the revenue beat. Separately, JPMorgan and Wells Fargo trimmed price targets (both to $35) though kept overweight ratings, reducing some upside implied by prior targets. Earnings Details (MarketBeat) JPMorgan / Wells Fargo Notes (Benzinga)

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.